Related Experiment Videos
New developments in the treatment of low high-density lipoprotein cholesterol
1Division of Cardiology-Room S3B06, University of Maryland Medical System, 22 South Greene Street, Baltimore, Maryland 21201, USA.
Insights
Low high-density lipoprotein (HDL) cholesterol is a risk factor for heart disease. HDL-raising agents, including statins and fibrates, show promise in managing cardiovascular events and improving outcomes in patients with low HDL levels.
Area of Science:
- Cardiovascular Medicine
- Lipidology
- Pharmacology
Background:
- Reduced levels of high-density lipoprotein (HDL) cholesterol are a significant risk factor for coronary artery disease (CAD) development and progression.
- Clinical outcome studies have confirmed the benefits of statin therapy in reducing cardiovascular events, even in patients with normal cholesterol levels.
- Subgroup analyses indicate that patients with low HDL cholesterol particularly benefit from statin therapy.
Purpose of the Study:
- To review the use of various HDL-raising agents in managing arteriographic progression.
- To explore the potential mechanisms of action of these HDL-raising agents.
- To highlight the importance of HDL-raising agents in treating high-risk patients with low HDL.
Main Methods:
- Review of clinical outcome studies involving statin therapy.
- Analysis of recent outcome trials on fibrate therapy.
- Examination of studies on HDL-raising agents, both singly and in combination.
- Discussion of potential mechanisms of action for HDL-raising therapies.
Main Results:
- Statin therapy has been verified to reduce the risk of initial or recurrent cardiovascular events.
- Subgroup analyses show that patients with low HDL cholesterol benefit from statin therapy.
- Recent fibrate therapy trials suggest a potential role for these medications in subjects with low HDL.
Conclusions:
- HDL-raising agents, including statins and fibrates, play a role in managing cardiovascular risk, especially in patients with low HDL levels.
- The mechanisms of action of these agents are crucial considerations for treating high-risk patients.
- Further research into HDL-raising therapies may offer improved strategies for cardiovascular disease prevention.
Abstract:
Reduced levels of high-density lipoprotein (HDL) cholesterol represent an important risk factor for the development and progression of coronary artery disease. In recent years, clinical outcome studies have verified that statin therapy may reduce the risk of initial or recurrent cardiovascular events in subjects with elevated or "normal" cholesterol levels. Subgroup analysis has also revealed that patients with low HDL benefit from this therapy. Two recently presented outcome trials using fibrate therapy also demonstrated a potential role for these medications in subjects with low HDL. The use of various HDL raising agents, singly or in combination on arteriographic progression and their potential mechanisms of action are reviewed. The latter may be an important consideration in the treatment of high-risk patients with low HDL.